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Neste artigo, desenvolvemos, validamos e aplicamos um método para separação e 
quantificação de porfirinas precursoras do grupo heme na urina de portadores de porfirias. 
Os isômeros coproporfirinogenio I e III (COPRO I e III), uroporfirinogenio I (URO I), 
heptacarboxilporfirinogenio I (HEPTA I), pentacarboxilporfirinogenio I (PENTA I) e 
hexacarboxilporfirinogenio (HEXA I) foram determinados em amostras coletadas de 24 pacientes 
de porfiria aguda intermitente e de porfiria cutânea tarda. Utilizou-se cromatografia líquida de alta 
eficiência (HPLC) e detector de fluorescência. As concentrações de porfirinas foram determinadas 
com precisão inter e intra-dias (< 5%) e exatidão dentro da faixa 95-99%. Os limites de detecção 
e quantificação das porfirinas, expressos em nmol L-1, foram os seguintes: URO I, 0,62 e 2,05; 
HEPTA I, 0,59 e 1,96; HEXA I, 0,54 e 1,81; PENTA I, 0,52 e 1,73; COPRO I, 2,03 e 6,77; e 
COPRO III, 0,43 e 1,44. O método descrito aqui obedece a parâmetros analíticos satisfatórios, com 
excelente relação custo-benefício, e foi aplicado a amostras de urina de portadores assintomáticos e 
pacientes de porfirias. Este método foi validado analiticamente e mostrou potencial para diagnóstico 
de portadores de diferentes tipos de porfirias, imediatamente antes ou durante crises, e até mesmo 
para monitorar um tratamento farmacológico.
We describe here the development, validation, quantification and application of a 
method for determination of heme porphyrin precursors in the urine of porphyric patients. 
The isomers coproporphyrinogen I and III (COPRO I and III), uroporphyrinogen I (URO I), 
heptacarboxylporphyrinogen I (HEPTA I), pentacarboxylporphyrinogen (PENTA I), and 
hexacarboxylporphyrinogen I (HEXA I) were analyzed. These six urinary heme precursors were 
determined in urine samples collected from 24 patients by high-performance liquid chromatography 
(HPLC) equipped with a fluorescence detector. The inter- and intra-day precision (coefficient of 
variation < 5%) and accuracy (95-99%) were evaluated. The limits of detection and of quantification 
of the porphyrins, expressed in nmol L-1, were as follows: URO I, 0.62 and 2.05; HEPTA I, 0.59 and 
1.96; HEXA I, 0.54 and 1.81; PENTA I, 0.52 and 1.73; COPRO I, 2.03 and 6.77; and COPRO III, 
0.43 and 1.44. The method described here satisfactorily results in an acceptable cost-benefit ratio, 
precision and speed for determining the concentrations of heme precursors in the urine of latent 
or symptomatic acute intermittent porphyria individuals or porphyria cutanea tarda carriers. Since 
it was analytically validated, this method may be used for accurate and reliable diagnostic reports 
to follow-up the onset of acute crisis in porphyria carriers to adopt preventive pharmacological 
treatment. 
Keywords: porphyrins, heme biosynthesis, acute intermittent porphyria, porphyria cutanea 
tarda, porphyria diagnosis, HPLC analysis of porphyrinogens
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Introduction
Porphyrias are a group of genetic and acquired 
rare disorders caused by enzymatic deficiencies in the 
heme biosynthetic pathway attributed to abnormally 
low enzymatic activities or inhibition by xenobiotics 
leading to the accumulation or deficit of heme precursors 
(Table 1).1,2 Acute porphyria occurs in all ethnic groups. 
In most European countries the estimated prevalence 
is 1-2 per 100,000 inhabitants, with acute intermittent 
porphyria (AIP) being the most common type of disorder. 
However, there is a much higher prevalence in the 
psychiatric population (210 per 100,000 in the United 
States),3 which has been attributed to misdiagnoses due to 
neuropsychiatric symptoms of porphyria, such as insomnia, 
abdominal pain, palpitations, and pain in the extremities, 
back, chest, neck or head.4 Other neuropsychiatric 
symptoms of porphyria also include seizures, agitation, 
hallucinations and other psychiatric symptoms, such as 
psychosis similar to schizophrenia.5,6 Late diagnosis can 
cause serious neurological and mental damage, and may 
lead to mortality, especially in the differential diagnosis of 
psychiatric patients.7,8
Like many hereditary diseases, porphyrias have an 
uneven distribution. For example, porphyria cutaneous 
tarda has a prevalence of 1:10,000,9 which varies between 
countries; the prevalence is 1:25,000 in North America, 
1:5,000 in Czechoslovakia, and 2-5 cases per million per 
year in the UK. There is no reported data for Brazilian AIP 
prevalence. Although porphyria cutanea tarda (PCT) is 
probably the most common of all porphyrias, its prevalence 
has not been well estimated, and no reliable data have been 
published so far. It is estimated that the prevalence of PCT 
in Spain is approximately 1:1,000 inhabitants. In the case 
of AIP, for example, the ratio is 1:20,000 inhabitants, while 
in northern Sweden it is 1:10,000. Porphyria variegata 
(PV) is particularly common among Afrikaners (white 
South Africans, especially Dutch descendants), with an 
incidence of 1:250. In South Africa, the prevalence of PV 
is 1:400. However, it is difficult to estimate the incidence of 
porphyria because many individuals remain asymptomatic 
throughout life.10 For early diagnosis and identification of 
the type of porphyria, samples of urine, blood and stool 
should be carefully examined by a laboratory with expertise 
in diagnosis of porphyria.
Heme occupies a critical position in the aerobic 
metabolic map. It is the prosthetic group of oxygen 
carrier proteins (hemoglobin, myoglobin), cytochromes 
in electron transport chains, and peroxidases, such as 
catalase and tryptophan-2,3-dioxygenase. In AIP, failure in 
5-aminolevulinic acid dehydratase (ALA-D) biosynthesis 
results in intracellular accumulation of the first and second 
heme precursors,11 namely, ALA and porphobilinogen 
(PBG), whereas in lead poisoning both ALA-D and 
ferrochelatase are inhibited by Pb2+ ion, ultimately 
preventing iron incorporation into the heme molecule, and 
release of the intermediates into the blood.12,13 Accumulation 
of specific heme precursors in some tissues and organs1-12 
triggers so-called “acute hepatic”, “hepatic cutaneous” and 
“erythropoietic cutaneous” clinical manifestations,14 which 
are accompanied by altered urinary and fecal excretion of 
heme intermediates.15
Table 1. Types of porphyrias and the corresponding altered urinary porphyrin (adapted from Alves et al.20)
Porphyria Clinical expression Enzymes altered Urinary porphyrin altered
Erythropoietic
CEP Photosensitivity URO III synthase URO I, COPRO I
EEP Photosensitivity ferrochelatase COPRO
Hepatic
Acute
ADP Visceral and neurologic ALA-D COPRO
AIP Visceral PBG-D URO, COPRO I 
HCP Visceral, neurologic and photosensitivity Uroporphyrinogen decarboxylase COPRO III
VP Visceral and neurologic Protoporphyrinogen IX oxidase COPRO I
Chronic
PCT Photosensitivity URO-D URO, HEPTA
HEP Visceral, neurologic and photosensitivity URO-D URO, HEPTA
CEP: congenital erythropoietic porphyria; EEP: erythropoietic protoporphyria; ADP: acute ALA-D deficiency porphyria; AIP: acute intermittent porphyria; 
HCP: hereditary coproporphyria; VP: variegate porphyria; PCT: porphyria cutanea tarda; HEP: hepatic erythropoietic porphyria; ALA: delta-aminolevulinic 
acid; ALA-D: aminolevulinate dehydratase; PBG-D: porphobilinogen deaminase; URO: uroporphyrin; COPRO: coproporphyrin; URO-D: uroporphyrinogen 
decarboxylase.
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Heme biosynthesis is initiated in the mitochondria 
from the reaction of glycine with succinyl-CoA to 
form ALA, which migrates into the cytosol where PBG 
is formed under the action of ALA-D.16,17 Porphyrin 
derivatives are formed by the condensation of the pyrrole 
rings of four molecules of PBG, yielding uroporphyrins 
(URO), which contain eight carboxyl groups, and are 
successively decarboxylated to the less polar intermediates14 
heptacarboxyl porphyrins (HEPTA), hexacarboxyl 
porphyrins (HEXA), pentacarboxyl porphyrins (PENTA), 
and coproporphyrins (COPRO), that contain four carboxyl 
groups. Porphyrin derivatives originating from PBG can be 
formed in two ways, spontaneously or enzymatically, and 
are denominated URO I, HEPTA I, HEXA I, PENTA I or 
COPRO I or URO III, HEPTA III, HEXA III, PENTA III 
or COPRO III. Porphyrins produced enzymatically in the 
cytosol are ultimately converted into protoporphyrinogen 
IX (PROTO IX) and protoporphyrin IX (PP IX), which 
migrate to the mitochondrial matrix where they coordinate 
with an iron ion in a reaction catalyzed by ferrochelatase 
to produce the heme molecule. 
Porphyrias can be genetically transmitted by autosomal 
dominant inheritance, with the exception of congenital 
erythropoietic porphyria (autosomal recessive),18 or 
can be chemically acquired by exposure of individuals 
to xenobiotics, such as lead, a condition referred to as 
lead poisoning, plumbism or saturnism.14 The excretion 
patterns of heme intermediates enable the classification 
of a case of porphyria and the establishment of the most 
suitable strategies for drug therapy and patient monitoring19 
(Table 1). Many spectrofluorometric techniques are 
available to detect porphyrin excretion in urinary fractions; 
however, gradient reversed-phase high-performance 
liquid chromatography (RP-HPLC) using C18 columns 
with fluorescence detection is an accessible methodology 
for most laboratories and is sensitive enough to detect 
at least five fractions.20 Here, we used a modified HPLC 
methodology to identify COPRO I and COPRO III isomers, 
which may also be applied to the diagnosis of other diseases 
that are based on alterations of normal heme.21
Recently, Balwani and Desnic published a comprehensive 
review on the diagnosis and treatment of the eight 
genetically distinguished porphyrias.1 Moreover, Danton 
and Lim discussed the reported methods for analyzing the 
heme biosynthetic metabolites and their oxidation products 
by HPLC/mass spectrometry (MS), which may eventually 
result in the characterization of the type of porphyria 
carried by a patient.22 Alternatively, several hypotheses for 
biochemically correlating the data on heme intermediates 
present in urine and blood with the clinical porphyric data 
have been discussed in the literature. Among them, a free 
radical- and oxidative stress-based hypothesis based on 
the accumulation of pro-oxidant ALA in tissue has been 
reinforced by biochemical data obtained from in vitro and in 
vivo studies with cell cultures and animal and human organs 
that are ALA-rich endogenously or due to experimental 
interventions.14,23
Laboratory diagnosis is achieved by the quantification 
of these metabolites present in the heme biosynthetic 
pathway and subsequent measurement of the enzyme 
activities related to the metabolites. The current accepted 
values for random urinary porphyrins in healthy individuals 
are as follows: URO: ≤ 30 nmol L-1; HEPTA: ≤ 7 nmol L-1; 
HEXA: ≤ 2 nmol L-1; PENTA: ≤ 5 nmol L-1 and total 
COPRO (I + III) ≤ 110 nmol L-1.24
We propose here a rapid, cheap and sensitive HPLC 
method to identify urinary porphyrin metabolites in patients 
in public hospital networks that include the distinction 
between COPRO I and III. Previous reports stress the 
importance of determining COPRO I and III isomer levels 
as biomarkers of arsenic poisoning,25 as exposed groups 
have been found to exhibit significantly higher COPRO I 
and III levels compared with those in the control group. 
Alterations in porphyrin concentrations are determined in 
urine samples from clinically identified porphyric patients 
compared to samples obtained from healthy individuals, 
thereby demonstrating the reliability of this method to 
identify the class of porphyria.
Experimental
HPLC method 
Urinary porphyrins were analyzed using a Shimadzu 
HPLC chromatograph (Kyoto, Japan) composed of 
the following parts: 1 RF 20A fluorescence fetector; 
1 DGU-20A5 degasser; 2 LC-20 AT liquid chromatography 
pumps; 1 SIL-20 HT auto sampler; 1 CTO-20A column 
oven, and 1 CBM-20A communications bus module, 
programmed for excitation at 400 nm and emission 
at 620 nm, and one integrator (CR7A PLUS). The 
column used was a reversed phase C18
 
HPLC column 
Phenomemex® (Torrance, CA, USA), model LiChrospher, 
125 × 4.00 mm, attached to a pre-column, 4.0 cm × 4.0 mm, 
both 5 mm RP-18, 100 Å, 5-µm particles, with a flow of 
1 mL min-1 and a 100 µL sample injection size.
A standard commercial lyophilized porphyrin kit was 
purchased from Sigma-Aldrich (St. Louis, MO, USA), 
which contains URO I dihydrochloride, synthetic COPRO I 
dihydrochloride, and COPRO III tetramethyl ester. In 
addition, a CMK-1A porphyrin acid chromatographic 
marker kit containing URO I dihydrochloride, HEPTA I 
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heptamethyl ester, HEXA I hexamethyl ester, PENTA I 
pentamethyl ester, and COPRO I tetramethyl ester was 
acquired from Frontier Scientific (Logan, UT, USA). 
Standard solutions of porphyrins suspended in HCl from 
Merck KGaA (Darmstadt, Germany) were prepared at 
concentrations of 6.0 and/or 3.0 nmol L-1. For the porphyrin 
analysis, 100 µL porphyrin aliquots were injected into 
the chromatograph at a flow rate of 1.0 mL min-1 with a 
total analysis time of approximately 43 min. Phase A was 
prepared using 1.0 mol L-1 ammonium acetate buffers 
(Synth, São Paulo, Brazil) with pH values of 4.0, 4.3, 4.6, 
4.9, 5.2, 5.4, 5.7 and 6.0, adjusted with 99% glacial acetic 
acid (Sigma-Aldrich) containing 10% acetonitrile. Phase B 
was prepared from 90% HPLC grade methanol and 10% 
acetonitrile (Merck KGaA). Elution was performed using 
the gradient program, starting with 100% phase A and 
0% phase B, followed by 10 min with 35% phase A at 
the selected pH and 65% phase B. Twenty minutes after 
separation of a given sample, the column was cleaned 
and stabilized. These sets of chromatographic variables 
allowed the separation of the porphyrin fractions due to 
clear-cut polarity differences based on the distinct number 
of porphyrin carboxyl groups. The choice of composition 
and separation program for the HPLC analysis of urinary 
porphyrins to attain optimization was guided by varying 
phase A. This study also intended to promote the separation 
of COPRO isomers I and III, of enzymatic and non-
enzymatic origins, respectively, and 10% acetonitrile was 
added in both phases to improve the resolution of analyte 
separation. The retention time, the area of the metabolite 
peaks and the number of theoretical plates were evaluated 
for phase A at different pH values.
Bioanalytical validation and statistical analysis 
The analytical validation of the method described 
here complies with the procedures and parameters 
recommended by the US Food Drug Administration 
(FDA).26 The following analytical parameters were 
evaluated here: specificity, linearity, precision, sensitivity, 
limit of detection, limit of quantification and accuracy. 
The calibration curves were determined using spiked 
urine samples containing six known concentrations of 
each analyte: 5, 50, 100, 500, 1,000 and 5,000 nmol L-1 
for URO, HEPTA, HEXA, PENTA, and COPRO I; and 7, 
70, 700, 1,700, 3,500, and 7,000 nmol L-1 for COPRO III.
The evaluation of the accuracy of the method was 
used to estimate the analyte recovery parameter, which 
can be defined as the ability of the method to approach the 
true analyte concentration in the real sample. Therefore, 
analyses were performed using three samples, with three 
different concentrations of each analyte and five replicates 
of each trial. 
The precision of the method was evaluated for each 
analyte at three different concentrations performed on 
the same day (intra-analysis precision) and by analysis of 
the same solutions on five different days (inter-analysis 
precision).
The sensitivity of the method was assessed by 
calculating the limits of detection and of quantification. 
The limit of quantification (LOQ) is defined as the 
smallest quantity in the sample that can be assayed under 
experimental conditions with a defined accuracy, with a 
coefficient of variation (CV) lower than 15%.
Patients studied
The study was approved by the institutional (Unifesp) 
ethics committee, according to the protocol number 
1964/10. Questionnaires were answered by 40 patients with 
a suspected or confirmed diagnosis of porphyria, referred by 
the Brazilian Porphyria Association (Associação Brasileira 
de Porfiria, ABRAPO). A kit for collecting random urine 
samples was mailed to the patients in a foam box, which 
contained two sterile, light-protected bottles containing 
5 g L-1 sodium bicarbonate (Synth). The terms of consent 
and the collection guidelines were included in the kit. 
Twenty four urine samples were obtained from patients 
between ages 17 and 70 years.
Storage and preparation of urine samples
Patient urine samples were collected in the morning, 
protected from light, kept on ice and delivered to the 
laboratory on the same day. Upon receipt, the samples 
were aliquoted and kept frozen at –80 °C until use. Then, 
2 mL of each urine sample were thawed and acidified with 
70 µL of HCl (Merck KGaA) to obtain a pH of ca. 2.0. 
After homogenization, the samples were filtered through 
a 0.22 mm membrane (Millipore Corporation, Billerica, 
MA, USA) and sonicated (Elma, Ultrasonic Digital S, 
Manchester, UK) for 20 min. All determinations were 
performed in parallel with authentic porphyrin samples.
Results and Discussion
The study of the pH effect of eluent A on the separation 
efficiency by fluorescence detection is summarized in 
Table 2. Standard samples of 100 nmol L-1 URO, HEPTA, 
HEXA, PENTA or COPRO I and 700 nmol L-1 COPRO III 
were injected into the HPLC equipment. The data presented 
in Table 2 and Figure 1 indicate that although the pH value 
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of 4.0 provides the largest numbers of theoretical plates, 
separation of COPRO I and III is not attained. However, 
by increasing the pH of the chromatographic phase, a good 
resolution of the chromatographic peaks of COPRO I and 
III and considerable amounts of theoretical plates were 
obtained. The best resolution was achieved with ammonium 
acetate buffer at pH 5.7 as eluent A (Table 2 and Figure 1). 
Partial separation of COPRO I and III was reached using 
these conditions and is consistent with the chromatograms 
obtained from both standard porphyrin solutions and a 
urine sample obtained from a porphyric patient (Figure 2).
The gradient started from 0% of eluent B, which made 
possible to separate the fractions based on their differences 
in polarity and helped eliminate polar interferences present 
in the samples. The HPLC separation parameters were also 
evaluated by spiking acidified urine samples with URO, 
HEPTA, HEXA, PENTA, COPRO I, and COPRO III 
standards. 
Student t-test was used to verify the linearity of 
deviations from the calibration curves obtained with the 
analytes. The experimental porphyrin concentration values 
(T) found by HPLC (n = 6) coincided with the calculated, 
nominal values with a confidence level of 95%. Calibration 
curves were constructed and analyzed statistically using a 
Student t-test for URO, HEPTA, HEXA, PENTA, COPRO I 
and III at concentrations of 5, 50, 100, 500, 1,000 and 
5,000 nmol L-1 for URO, HEPTA, HEXA and COPRO I, 
and 7, 70, 700, 1,700, 3,500 and 7,000 nmol L-1 for COPRO 
III. The equations found were y = 3.29403x + 3625.6; 
y = 3.07211x + 220841; y = 3.36552x + 118242; 
y = 3.33461x + 150771; y = 3.71105x + 281962; 
y = 1.00796x + 837120, respectively. The respective 
linear correlation coefficients (r2) were all above 0.99, thus 
confirming the linearity of the method. The evaluation of 
the accuracy of the method is displayed in Table 3 and 
demonstrates satisfactory recovery values for all analytes 
at all concentrations tested. The recovery percentages range 
from 85 to 115%, which is required by the FDA. 
The precision of the method evaluated based on 
the intra- and inter-assay analysis for URO, HEPTA, 
HEXA, PENTA, COPRO I and III determinations are in 
accordance with the FDA recommendations,26 all of which 
exhibited CV below 15%. During the chromatographic 
analysis of the patients, a mixture containing six diluted 
metabolites in urine samples from donors was injected 
Table 2. Retention times, peak areas and theoretical plates of the HPLC separation of six porphyrins obtained at pH levels varying from 4.0 to 6.0
pH 4.0 pH 4.3 pH 4.6 pH 4.9 pH 5.2 pH 5.4 pH 5.7 pH 6.0
tR TP tR TP tR TP tR TP tR TP tR TP tR TP tR TP
URO 2.1 32.8 6.3 298.7 6.4 857.9 3.2 105.3 4.1 111.8 4.4 162.8 2.0 94.1 1.7 60.1
HEPTA 5.0 58.8 9.0 3153.1 9.0 598.5 7.3 1407.6 7.8 477.1 7.9 449.7 5.5 211.6 2.8 72.9
HEXA 9.5 314.4 11.5 847.2 11.4 1071.3 10.2 737.9 10.5 1674.6 10.6 2312.1 8.7 2335.8 7.2 1037.7
PENTA 12.7 2164.5 13.6 1341.7 13.5 1602.9 12.7 1404.0 12.9 2053.4 12.9 4652.3 11.2 5702.0 10.0 2164.8
COPRO I
15.9 809.9
16.1 1658.2 15.8 5803.3 15.1 11606.9 15.1 5801.9 15.1 10958.1 13.5 12718.0 12.4 4185.2
COPRO III 16.5 838.6 16.3 951.3 15.5 1073.1 15.6 5889.7 15.6 1177.0 14.1 1199.3 13.2 4735.5
tR: retention time; TP: theoretical plates.
Figure 2. Comparative HPLC/fluorescence traces obtained for a standard 
mixture of porphyrins (dashed line) and the urine of a porphyric patient 
(solid line). Eluent A: 1.0 mol L-1 ammonium acetate buffer containing 
10% acetonitrile at pH 5.7. Eluent B: methanol:acetonitrile (9:1, v/v). 
Patient 2 was clinically diagnosed as an acute intermittent porphyria 
carrier. Porphyrin concentration was 500 nmol L-1. 
Figure 1. Theoretical plates for six urinary porphyrins upon the variation 
of pHs values. Porphyrin concentration was 500 nmol L-1. 
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to confirm that the retention times and chromatographic 
resolution were reproduced, which was indeed observed 
in all analyses.
The sensitivity of the method was assessed by 
calculating the limits of detection and quantification 
expressed in nmol L-1 as follows, respectively: URO, 
0.62 and 2.05; HEPTA, 0.59 and 1.96; HEXA, 0.54 and 
1.81; PENTA, 0.52 and 1.73; COPRO I, 2.03 and 6.77; 
and COPRO III, 0.43 and 1.44. Although chromatograms 
demonstrate that there is partial resolution of COPRO I and 
III, validation data meet the FDA guidelines and can be 
used to analyze patient urine samples. These data document 
the usefulness of the method for detecting and quantifying 
porphyrin metabolites with high sensitivity. Similar results 
were obtained by other authors using different HPLC 
methodologies.27,28 The validated method was then used 
to analyze random urine samples from 24 patients whose 
observed porphyrin concentrations are displayed in Table 4.
Healthy individuals displayed a typical urinary 
porphyrin excretion pattern, with 2-8 times more 
COPRO III than COPRO I (Table 4). To the best of our 
knowledge, no reference values for the COPRO porphyrins 
have been reported. The urinary porphyrin data suggest that 
patients with an AIP diagnosis (Table 4) exhibit augmented 
total COPRO urinary levels, even when they are not in 
crisis. Some of these patients belong to the same family and 
were clinically confirmed or suspected to be AIP carriers on 
the basis of symptoms, such as intense abdominal pain, but 
only patient No. 2 (chromatogram depicted in Figure 2) was 
clearly under acute crisis. This finding is important because 
minor changes in metabolic urinary porphyrin patterns 
might indicate the onset of crisis, allowing preventive 
medication to avoid further patient suffering.
Patient 14 exhibited symptoms characteristic of both 
PCT and AIP. As reported in the literature,18,29 PCT patients 
exhibit skin blemishes when exposed to sunlight, which is 
characteristic of PCT, and abdominal pain, which is typical 
of AIP. Changes were detected in HEPTA, HEXA, PENTA, 
COPRO I and III. 
Patient 15 displayed alterations in HEPTA, HEXA, 
PENTA, COPRO I and III urinary concentrations and skin 
lesions, which suggest PCT disorder. Accordingly, his 
anamnesis registered psychological disturbances that are 
characteristic of AIP. Moreover, the patient genetic report 
revealed small changes in some of the enzymes in the heme 
biosynthetic pathway, such as alterations in activity of the 
heme biosynthetic enzyme URO III synthase, a deficiency 
in which massive porphyrin accumulation in blood cells 
results and is responsible for hemolytic anemia and skin 
photosensitivity.30,31
A reliable diagnosis of PCT via HPLC urinary analysis 
seems to be more complex because all porphyrin - URO, 
HEPTA, HEXA, PENTA, or total COPRO - levels do not 
appear to follow a reproducible pattern, but are altered. 
These findings also demand further clarification, as minor 
changes in metabolic urinary porphyrin patterns might 
denounce the onset of crisis and recommend preventive 
treatment. 
Of the 24 patients referred by ABRAPO who had 
their samples analyzed in our study, 83.3% exhibited 
significant changes in one or more metabolites of the 
heme biosynthetic pathway, suggesting that the biomedical 
characterization of this rare health condition might 
actually be methodologically simple. Moreover, we may 
also consider the exposure of individuals to chemicals, 
such as polychlorinated biphenyls, hexachlorobenzene, 
pentachlorophenol, dioxins and heavy metals (arsenic, lead 
and mercury), which have a well-known risk of inducing 
porphyria and should obviously be avoided.32,33 In addition, 
these factors can cause porphyria in individuals with no 
documented genetic predisposition as an acquired toxin-
induced condition. Public policies adopted in developed 
countries to educate and monitor people who are at risk 
of lead poisoning have dramatically lowered instances of 
neurotoxicity in children, adolescent behavioral problems, 
Table 3. Recovery and accuracy of the HPLC method developed 
to determine URO, HEPTA, HEXA, PENTA, COPRO I and III 
concentrations in urine
Analyte Concentration / (nmol L-1)
Recovery / 
%
Intra-assay / 
(CV%)
Inter-assay / 
(CV%)
URO 100 108.2 2.4 1.3
500 105.1 7.6 2.6
1,000 109.6 3.2 2.7
HEPTA 100 93.9 5.1 2.3
500 111.2 6.2 1.3
1,000 92.5 14.1 1.0
HEXA 100 90.9 6.4 3.2
500 104.5 14.9 2.2
1,000 104.8 1.9 0.9
PENTA 100 91.0 12.4 2.3
500 114.5 11.5 0.6
1,000 103.1 1.3 0.7
COPRO I 100 100.7 5.8 1.0
500 109.4 7.3 2.1
1,000 89.5 1.8 2.8
COPRO III 700 112.4 10.4 1.8
1,700 99.2 12.5 5.1
3,500 99.8 3.8 1.6
CV: coefficient of variation.
Bioanalytical Studies of Porphyric Disorders Using HPLC with Fluorescence Detection J. Braz. Chem. Soc.1924
and societal economic losses.34 HPLC fluorescence 
detection proved to be an efficient and inexpensive (about 
US$ 20.00 per analysis) tool for the quantitative analysis 
of the six metabolites studied here. Of the examined 
patients, only one was in AIP crisis, while the remaining 
twenty-three patients were asymptomatic. 
Finally, we emphasize the potential importance of the 
separation of the two isomers COPRO I and III achieved 
here because it may help clarify the type of porphyria. 
In this regard, the COPRO I:COPRO I / (I + III) ratio is 
important in the diagnosis of Dubin-Johnson syndrome.35,36 
This syndrome is attributed to the mutation of the ABCC2 
gene, which is associated with a high excretion rate of 
COPRO I. This gene encodes the multidrug resistance-
associated protein 2 (MRP2), which is involved in the 
secretion of numerous drugs and endogenous substrates.37,38 
Reference values are available in the literature only as the 
sum of these two isomers, given that current analyses are 
not able to separate COPRO I and III, although the distinct 
enzymatic route that produces COPRO III has already been 
identified. 
Porphyria is classified as a rare disease, and its 
definition is therefore dependent upon the time period and 
geographic area being considered.39 However, patients 
with rare diseases face the challenges of a lack of scientific 
knowledge and competent medical professionals that can 
provide an accurate diagnosis, which prevents the family 
and patient from identifying the disease, triggering the 
patient’s symptoms in order to prescribe him an appropriate 
treatment.
In Brazil, ABRAPO was founded on 07/21/2006 to 
provide support to patients and their families, as well 
as raise awareness of porphyria patients so that they are 
better known, diagnosed and treated. According to the 
Paraná State Decree 15,781 of 02/21/2008, ABRAPO was 
declared of public interest. The activities and webpage 
Table 4. Urinary porphyrin concentrations found in urine samples collected from 24 patients diagnosed as porphyria carriers
Porphyrins / 
(nmol L-1)
URO HEPTA HEXA PENTA COPRO I COPRO III COPRO I + III COPRO I/III 
ratio
Supposed 
diagnosis
RV 30.0 7.0 2.0 5.0 NE NE 110.0 NE Healthy
P 1 14 5.1 1.1 1.2 16.3 45.4 61.7 0.36
P 10 4.1 3.3 2.0 2.9 17.4 54.7 72.1 0.32
P 11 5.4 2.6 1.4 1.8 8.5 59.4 67.9 0.14
P 21 1.7 0.5 0.4 0.8 10.1 68.5 78.6 0.15
P 16 2.9 3.9 2.8 3.6 22.9 92.7 115.6 0.25 AIP
P 2 90 83.4 63.8 207.9 94.7 3155.9 3250.6 0.03
P 13 14.6 16.8 14.8 14.6 34.7 131.5 166.2 0.26
P 22 5.4 0.7 0.4 1.4 21.4 124.2 145.6 0.17
P 23 5.4 1.5 0.6 2.4 31.4 164.1 195.5 0.19
P 4 5.6 3.2 0.6 1.9 30.3 294.7 325 0.10
P 5 3.6 2.5 0.3 2.1 13.2 160.9 174.1 0.08
P 6 7.8 5.0 3.0 3.9 28.8 322.3 351.1 0.09
P 12 21.0 3.5 1.1 1.5 20.3 92.2 112.5 0.22
P 19 7.4 0.6 1.1 1.4 45.9 209.4 255.3 0.22
P 17 5.4 4.5 1.6 4.2 18.4 163.0 1814.4 0.11
P 7 2.7 10.6 10.9 13.0 15.7 55.6 71.3 0.28 PCT
P 8 5.5 5.5 4.7 6.0 23.2 77.3 100.5 0.30
P 9 0.4 5.4 2.7 4.3 50.1 136.2 186.3 0.37
P 3 4.4 7.9 1.8 13.9 43.1 616.4 659.5 0.07
P 24 8,1 5,1 3,3 3,5 17,4 83,4 100,8 0.21
P 14 11.0 7.4 5.6 6.3 41.9 146.1 188.0 0.29
P 18 170 2.1 16.5 11.4 24.3 54.6 78.9 0.45
P 15 16.4 20.9 3.7 6.9 45.2 113.7 158.9 0.40
P 20 17.1 6.3 1.2 24.3 26.4 347.1 373.5 0.08
RV: reference values (healthy); P: patient; NE: not established.
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(www.porfiria.org.br) of this association make it possible 
to exchange information, guidelines for access to diagnosis, 
treatment, and integration between physicians and patients 
from different regions of Brazil. Support, information 
and guidance are provided via the Internet, telephone and 
e-mails. In 2011, the average number of monthly e-mails 
sent to patient’s families was 180. These e-mails contained 
information regarding major medical issues on hematin 
treatment, the list of banned drugs, and clinical tests for 
diagnosis, as well as general orientation. For dissemination, 
information and guidance, study groups, lectures, and patient 
meetings were also conducted, as well as participation in 
national and international conferences and other events. 
Until 12/31/2011, ABRAPO had 292 registered patients, 
and in May 2012, it went up to 310, which still does not 
represent the real number of carrier families known by the 
association. According to the monthly average consultation, 
ABRAPO hears approximately 06 patients per day with 
requests for information.
ABRAPO includes information for physicians, which 
has been translated into Portuguese by the American 
Porphyria Foundation, a result of the Global Porphyria 
Alliance site. The porphyria guidelines from the Brazilian 
Medical Association are nearing completion. Based on 
Google Analytics reports from 2011, the ABRAPO site 
received 21,413 visits, including 20,402 from Brazil (São 
Paulo, Rio de Janeiro, Curitiba, Belo Horizonte, Brasília, 
Salvador, Fortaleza, Campinas, Porto Alegre, and Recife 
were the 10 cities with the highest number of visits) 
and 1011 from other countries, with 436 from Portugal. 
Of these, 16,945 (79.13%) were new visitors and 4,468 
(20.87%) were accessing the site again.
These data demonstrate the importance of information 
on rare maladies, which may have access to specialized 
professionals, specific medications, contact with other 
patients and various clarifications. It is difficult to 
diagnose and treat porphyria. Although not officially, 
laboratories and hospitals with specialties in porphyria 
can be found in the Brazilian Universal Health System 
(public and free system). Hematin is the only drug used 
to regulate the metabolism of heme during attacks of 
acute porphyria. This drug is not produced in Brazil, 
and the request for registration with the National Health 
Surveillance Agency has not been answered. Its high cost 
prevents access by patients unless it is required by judicial 
order. This further complicates the arrival of the drug in 
a timely manner for the patient. However, in a meeting 
of the Ministry of Health in Brasília, on April 26, 2011, 
with various supporting institutions, a working group 
was formed regarding people with rare diseases in the 
Brazilian Universal Health System.
Conclusions
The HPLC/fluorescence detection method reported here 
facilitates the accurate, sensitive and inexpensive separation 
of six heme precursors as compared to mass spectrometry, 
for example. This method can be an important tool in 
public hospitals in continental countries, such as Brazil, to 
screen for patients and relatives with and without porphyria 
symptoms. We emphasize that all patients sent samples via 
regular mail. The diagnosis of AIP carriers is particularly 
important for anticipating the manifestation of acute crises, 
which can be fatal, and also to therapeutically monitor 
patients with chronic porphyria. Moreover, it may help the 
diagnosis of other diseases that are based on alterations in 
normal heme production or differential excretion of these 
isomers, which reportedly occurs, for example, in Dubin-
Johnson syndrome and arsenic poisoning.28
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